Clinical status of capecitabine in the treatment of breast cancer

ONCOLOGY

Volumn 15, Issue 1 SUPPL. 2, 2001, Pages 69-72

  Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; PRODRUG;

BREAST TUMOR; CLINICAL TRIAL; FEMALE; FORECASTING; HUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; DEOXYCYTIDINE; FEMALE; FORECASTING; HUMANS; NEOPLASM RECURRENCE, LOCAL; PRODRUGS; TREATMENT OUTCOME;

EID: 0035235721     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997.
2. Heidelberger C, Chaudhari N, Danneberg P, et al: Fluorinated pyrimidines: A new class of tumor-inhibitory compounds. Nature 179:663-666, 1957.
3. Cameron D, Gabra H, Leonard R: Continu-ous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 70:120-124, 1994.
4. Chu L, Sutton L, Peterson B, et al: Continuous-infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. J Infus Chemother 6:211-216, 1996.
5. Christophidis N, Vajda F, Lucas I, et al: Fluorouracil therapy in patients with carcinoma of the large bowel: A pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 3:330-336, 1978.